Answers are grounded in this paper and cite their sources.
11.4 mg of a ceramide hexahexoside (B-I) and 16.4 mg of a ceramide octahexoside (B-II) as blood group B-active glycosphingolipids composed of glucose, galactose, N-acetylglucosamine and fucose (molar ratios 1:3:1:1 and 1:4:2:1 respectively) have been isolated from 6,400 ml of packed human B erythrocytes. This yield is greater by more than the 13-fold amount of B-I glycosphingolipid and the 20-fold amount of B-II glycosphingolipid which has hitherto been isolated from human erythrocytes. The B-active glycosphingolipids isolated represent about 0.04% of the erythrocyte membrane and in consequence must be regarded as the main representants of B properties of the erythrocytes as far as they have been investigated up to this time. This high yield was achieved by a simple and conservative erythrocyte membrane preparation without loss of serological activity and by the improvement of some chromatographical methods which permitted a high purification without the acetylation-deacetylation procedure. Purity was checked by gas-liquid chromatographical analysis of the sugars as their alditol acetates and by the hemagglutination inhibition technique. 1.7 x 10-8 g of each of these glycosphingolipids completely inhibit the agglutination of human B erythrocytes by 4 hemagglutination units of normal human anti-B sera. A ceramide tetrahexoside and a glycolipid fraction with a high H activity could also be isolated which possibly are blood group-intermediate substances. Lewis blood group-active glycosphingolipids characterized by the hemagglutination inhibition test and by passive hemagglutination are trace constituents of other glycosphingolipid fractions.
No takes yet. Share an insight, caveat, or question.
Hanfland et al. (1975) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: